Provided by Tiger Trade Technology Pte. Ltd.

Evommune

6.02
-0.2000-3.22%
Volume:138.46K
Turnover:845.52K
Market Cap:218.48M
PE:-2.31
High:6.25
Open:6.25
Low:6.02
Close:6.22
52wk High:33.20
52wk Low:6.02
Shares:36.29M
Float Shares:19.98M
Volume Ratio:0.25
T/O Rate:0.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6090
EPS(LYR):-11.2228
ROE:-52.11%
ROA:-31.99%
PB:0.79
PE(LYR):-0.54

Loading ...

US Stocks on the MOVE-Cardinal Health, nVent, Acuity

Reuters
·
Oct 02

Evommune Gains After Eczema Drug Meets Mid-Stage Trial Goal

Reuters
·
Oct 01

Evommune presents Phase 2a PoC data on EVO301 at EADV Congress

TIPRANKS
·
Oct 01

Evommune Says Phase 2a Trial Shows Evo301 Cuts EASI 55% at Week 12 in Atopic Dermatitis

Reuters
·
Oct 01

Evommune Announces Late-Breaker Presentation of Phase 2a Data for Evo301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress

THOMSON REUTERS
·
Sep 24

U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs

Reuters
·
Sep 10

Evommune Price Target Cut to $22.00/Share from $28.00 by Leerink Partners

Dow Jones
·
Sep 10

Sweden's Biovica Q1 Sales Rise on Pharma Services Growth

Reuters
·
Sep 09

Stifel Nicolaus Remains a Buy on Evommune, Inc. (EVMN)

TIPRANKS
·
Sep 09

Analysts Are Bullish on These NA Stocks: Douglas AG (DOUDF), Evommune, Inc. (EVMN)

TIPRANKS
·
Sep 09

U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software

Reuters
·
Sep 09

Sector Update: Healthcare Stocks Mixed Premarket Wednesday

MT Newswires Live
·
Sep 09

Evommune price target lowered to $21 from $29 at RBC Capital

TIPRANKS
·
Sep 09

Leerink Partners Sticks to Its Buy Rating for Evommune, Inc. (EVMN)

TIPRANKS
·
Sep 09

U.S. Stocks on the MOVE-Meta, Chime Financial, ServiceTitan

Reuters
·
Sep 09

Evommune, Inc. : Raymond James Cuts Target Price to $18 from $32

THOMSON REUTERS
·
Sep 09

RBC Cuts Price Target on Evommune to $21 From $29, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Sep 09

Analysts Conflicted on These NA Names: Evommune, Inc. (EVMN) and Chime Financial, Inc. Class A (CHYM)

TIPRANKS
·
Sep 09

Evommune Slides 18.1% Premarket After Co's Eczema Drug Misses Main Goal in Mid-Stage Trial

THOMSON REUTERS
·
Sep 09

U.S. Research Roundup-Argan, Mastec, Oracle

Reuters
·
Sep 09